Mouthwash may fight Chemo's bitter side effect
NCT ID NCT07573787
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a mouthwash made with homoeriodictyol sodium to reduce bitter taste caused by chemotherapy in women with gynecologic cancers. The study aimed to see if the mouthwash could improve taste and food intake. Only 15 participants were enrolled, and the trial was terminated early.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- homoeriodictyol sodium mouthwash
- What this could lead to
- If it works, this mouthwash could help reduce the bitter taste that many women experience during chemotherapy, making it easier to eat and maintain weight.
- What could go wrong
- This is a very small pilot study with only 15 participants and was terminated early. The results may not be reliable or apply to a larger population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Jan 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients (\>18 years) with histologically confirmed gynaecological malignancy * Planned chemotherapy * Written informed consent * Expected patient compliance Exclusion Criteria: * Vomiting (CTCAE 4.03) \> Grade 2 (3-5 episodes within 24 hours) * Nasogastric tube or PEG tube * Previous platinum-based chemotherapy * Conditions that impair taste perception (e.g., infections in the oral cavity)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gynecologic cancers are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of Vienna
Vienna, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI chatbot may sharpen nurses' cancer care decisions
- A simple drain may slash wound infections after gynecologic cancer surgery
- New digital tool aims to boost fertility awareness in cancer patients
- Rare surgery for recurrent cancer: how does it affect quality of life?
- BRCA study aims to unlock cancer secrets
- New combo aims to fix chemo side effect in cancer survivors